A device for subdermal insertion of solid media may include a front body defining a window. A device may include a rear body selectively coupled to the front body. A device may include a needle hub received within the front body and the rear body and movable between an extended position and a retracted position. A device may include a trocar coupled to the needle hub and including a payload retention feature.
A device for subdermal insertion of solid media may include a front body defining a window. A device may include a rear body selectively coupled to the front body. A device may include a needle hub received within the front body and the rear body and movable between an extended position and a retracted position. A device may include a trocar coupled to the needle hub and including a payload retention feature.
An improved long-acting injectable depot suspension formulation of LB displaying progestational effects which overcomes the aggregation and physical instability of LB injectable depot products, and also provides a longer duration of action of at least 4 months. Potential uses of this formulation include but are not limited to contraception and treatment or prevention of progestin/progesterone-sensitive reproductive tract dysfunctions and disorders.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 9/00 - Medicinal preparations characterised by special physical form
An improved long-acting injectable depot suspension formulation of LB displaying progestational effects which overcomes the aggregation and physical instability of LB injectable depot products, and also provides a longer duration of action of at least 4 months. Potential uses of this formulation include but are not limited to contraception and treatment or prevention of progestin/progesterone-sensitive reproductive tract dysfunctions and disorders.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 9/00 - Medicinal preparations characterised by special physical form
An improved long-acting injectable depot suspension formulation of LB displaying progestational effects which overcomes the aggregation and physical instability of LB injectable depot products, and also provides a longer duration of action of at least 4 months. Potential uses of this formulation include but are not limited to contraception and treatment or prevention of progestin/progesterone-sensitive reproductive tract dysfunctions and disorders.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure provides synthetic mRNA a coding region encoding a protein involved in oocyte maturation or a variant thereof. Methods of using the disclosed synthetic mRNA in oocyte maturation or in vitro fertilization are also provided.
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
7.
STABILIZATION OF ANTIGENS FOR LONG TERM ADMINISTRATION IN TRANSDERMAL MICRONEEDLE PATCHES
Described herein are compositions and methods for stabilizing RNA and protein antigens for long-term storage and use in transdermal microneedle patches, methods for filling microneedles, and methods of use. A stabilized RNA vaccine composition comprises: a complex of RNA with one or more cationic polymers; and one or more cationic lipid entities. A method for stabilizing RNA comprises: forming a complex comprising the RNA with one or more cationic polymers; mixing the complex with one or more cationic lipid entities comprising liposomes or lipid nanoparticles to form a lipid mixture; and drying the lipid mixture under vacuum. The compositions and methods may be employed in the preparation of vaccine medicaments.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 9/00 - Medicinal preparations characterised by special physical form
Various implementations include an ultrasound needle guidance device. The device includes a coupling body and at least one needle holder portion. The coupling body is configured to fixedly couple to an ultrasound probe that is able to produce an ultrasonic beam along a scanning plane. The needle holder portion has a rotational axis and defines a needle opening having an opening central axis extending perpendicularly to the rotational axis. The needle holder portion is rotationally coupled to the coupling body such that the needle holder portion is rotatable about the rotational axis relative to the coupling body from a first position to a second position. The needle holder portion is configured such that, when the coupling body is coupled to the ultrasound probe, the opening central axis is disposed within the scanning plane in all positions in a range from the first position to the second position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
Various implementations include an ultrasound needle guidance device. The device includes a coupling body and at least one needle holder portion. The coupling body is configured to fixedly couple to an ultrasound probe that is able to produce an ultrasonic beam along a scanning plane. The needle holder portion has a rotational axis and defines a needle opening having an opening central axis extending perpendicularly to the rotational axis. The needle holder portion is rotationally coupled to the coupling body such that the needle holder portion is rotatable about the rotational axis relative to the coupling body from a first position to a second position. The needle holder portion is configured such that, when the coupling body is coupled to the ultrasound probe, the opening central axis is disposed within the scanning plane in all positions in a range from the first position to the second position.
Various implementations include a device for subdermal insertion of solid media. The device includes a handle having a central plane, a needle, and a guide. The needle is coupled to and extending from the handle. The needle has a needle longitudinal axis and a distal tip disposed along the needle longitudinal axis and the central plane. The guide extends from the handle. The guide has a distal end disposed along the central plane. The distal end of the guide is disposed further than the distal tip of the needle from the handle. The distal tip of the needle is visible when viewed along the central plane and perpendicular to an axis including the distal end of the guide and the distal tip of the needle.
Various implementations include a device for subdermal insertion of solid media. The device includes a handle having a central plane, a needle, and a guide. The needle is coupled to and extending from the handle. The needle has a needle longitudinal axis and a distal tip disposed along the needle longitudinal axis and the central plane. The guide extends from the handle. The guide has a distal end disposed along the central plane. The distal end of the guide is disposed further than the distal tip of the needle from the handle. The distal tip of the needle is visible when viewed along the central plane and perpendicular to an axis including the distal end of the guide and the distal tip of the needle.
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
12.
STABILIZATION OF ANTIGENS FOR LONG TERM ADMINISTRATION IN TRANSDERMAL MICRONEEDLE PATCHES
Described herein are compositions and methods for stabilizing RNA and protein antigens for long-term storage and use in transdermal microneedle patches, methods for filling microneedles, and methods of use. A stabilized RNA vaccine composition comprises: a complex of RNA with one or more cationic polymers; and one or more cationic lipid entities. A method for stabilizing RNA comprises: forming a complex comprising the RNA with one or more cationic polymers; mixing the complex with one or more cationic lipid entities comprising liposomes or lipid nanoparticles to form a lipid mixture; and drying the lipid mixture under vacuum. The compositions and methods may be employed in the preparation of vaccine medicaments.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A pharmaceutical composition and methods for using the pharmaceutical composition are disclosed. The pharmaceutical composition may include a therapeutically effective amount of one or more antiviral active pharmaceutical ingredients and a pharmaceutically acceptable excipient. The pharmaceutical composition may be a solid dosage form, wherein the solid dosage form provides sustained release of the antiviral active pharmaceutical ingredient when administered as a vaginal or rectal insert.
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The Regents of the University of California Santa (USA)
The United States of America Department of Health (USA)
Thomas Jefferson University (USA)
Inventor
Maloney, David J.
Luci, Diane K.
Jadhav, Ajit
Holman, Theodore
Nadler, Jerry L.
Holinstat, Michael
Taylor-Fishwick, David
Simeonov, Anton
Yasgar, Adam
Mckenzie, Steven
Abstract
Human lipoxygenases (LOXs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Platelet-type 12-(S)-LOX (12-LOX) is of particular interest because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Disclosed herein is the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide-based scaffold. The compounds display nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In addition to possessing favorable ADME properties, the compounds also inhibit PAR-4 induced aggregation and calcium mobilization in human platelets, and reduce 12-HETE in mouse/human beta cells. The compounds can also be used in methods for treating or preventing a 12-lipoxygenase mediated disease or disorder.
C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 211/28 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
C07D 213/76 - Nitrogen atoms to which a second hetero atom is attached
C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D 235/30 - Nitrogen atoms not forming part of a nitro radical
C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 277/52 - Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
16.
PIC1 VARIANTS WITH IMPROVED SOLUBILITY AND METHODS OF USING THE SAME
A method of improving the lifespan of transfused platelets is described. The method may be useful for patients with alloimmunozation who are refractory to transfused platelets. A method of treating delayed hemolytic transfusion reaction is also described. Also described are PIC1 peptide variants with improved solubility and activity.
A skin patch for the transdermal administration of drags, and processes of manufacture, uses thereof, and corresponding methods of treatment therewith.
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
18.
PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING ON DEMAND SOLID DOSAGE FORMULATIONS
A pharmaceutical composition and methods for using the pharmaceutical composition are disclosed. The pharmaceutical composition may include a therapeutically effective amount of one or more antiviral active pharmaceutical ingredients and a pharmaceutically acceptable excipient. The pharmaceutical composition may be a solid dosage form, wherein the solid dosage form provides sustained release of the antiviral active pharmaceutical ingredient when administered as a vaginal or rectal insert.
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
19.
PIC1 PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF DRUG-INDUCED IMMUNE HEMOLYTIC ANEMIA
Compositions and methods for treating hemolytic anemia are described. A classical complement pathway inhibitor is used to treat hemolytic anemia, for example ceftriaxone-induced complement- mediated hemolysis. A Complement Hemolysis Using Human Erythrocytes (CHUHE) assay is also described where exogenous ceftriaxone is added to a patient's serum to show enhanced lysis of the patient's erythrocytes in vitro. Ceftriaxone is shown to initiate classical complement pathway - mediated hemolysis by ex vivo reversal with Peptide Inhibitor of Complement Cl (PIC1).
An improved long-acting injectable depot suspension formulation of LB displaying progestational effects which overcomes the aggregation and physical instability of LB injectable depot products, and also provides a longer duration of action of at least 4 months. Potential uses of this formulation include but are not limited to contraception and treatment or prevention of progestin/progesterone-sensitive reproductive tract dysfunctions and disorders.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 9/00 - Medicinal preparations characterised by special physical form
The Regents of the University of California Santa (USA)
The United States of America Department of Health (USA)
Thomas Jefferson University (USA)
Inventor
Maloney, David J.
Luci, Diane K.
Jadhav, Ajit
Holman, Theodore
Nadler, Jerry L.
Holinstat, Michael
Taylor-Fishwick, David
Simeonov, Anton
Yasgar, Adam
Mckenzie, Steven
Abstract
Human lipoxygenases (LOXs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Platelet-type 12-(S)-LOX (12-LOX) is of particular interest because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Disclosed herein is the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide-based scaffold. The compounds display nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In addition to possessing favorable ADME properties, the compounds also inhibit PAR-4 induced aggregation and calcium mobilization in human platelets, and reduce 12-HETE in mouse/human beta cells. The compounds can also be used in methods for treating or preventing a 12-lipoxygenase mediated disease or disorder.
C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 235/30 - Nitrogen atoms not forming part of a nitro radical
C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 277/52 - Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
C07D 211/28 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
C07D 213/76 - Nitrogen atoms to which a second hetero atom is attached
C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
22.
Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1
Methods of preserving and/or protecting pancreatic beta cells by inhibiting NOX-1. In a further aspect, NOX-1 inhibitors are administered to a subject in order to preserve and/or protect beta cells in the prevention or treatment of diabetes. NOX-1 inhibitors are also disclosed.
A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 279/20 - [b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
An improved long-acting injectable depot suspension formulation of LB displaying progestational effects which overcomes the aggregation and physical instability of LB injectable depot products, and also provides a longer duration of action of at least 4 months. Potential uses of this formulation include but are not limited to contraception and treatment or prevention of progestin/progesterone-sensitive reproductive tract dysfunctions and disorders.
The invention relates to processes for mitochondrial microinjection in oocytes. The processes involve isolating mammalian mitochondria for microinjection in oocytes to increase their mitochondrial activity. Microinjected mitochondria may be isolated from mammalian platelets and incubated in a favorable medium prior to microinjection. Oocytes that are microinjected with mitochondria obtained from the processes of the invention are shown to have a higher rate of fertilization and blastocyst formation when the processes disclosed herein are used concurrently with in vitro fertilization procedures. The invention relates generally to a process for treating deficiencies in mitochondrial activity in oocytes, a process for isolating mitochondria from mammalian platelets, and/or a process for preparing mitochondria for microinjection in oocytes.
The Regents of the University of California Santa Cruz (USA)
The United States of America Department of Health and Human Services (USA)
Thomas Jefferson University (USA)
Inventor
Maloney, David J.
Luci, Diane K.
Jadhav, Ajit
Holman, Theodore
Nadler, Jerry L.
Holinstat, Michael
Taylor-Fishwick, David
Simeonov, Anton
Yasgar, Adam
Mckenzie, Steven
Abstract
Human lipoxygenases (LOXs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Platelet-type 12-(S)-LOX (12-LOX) is of particular interest because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Disclosed herein is the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide-based scaffold. The compounds display nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In addition to possessing favorable ADME properties, the compounds also inhibit PAR-4 induced aggregation and calcium mobilization in human platelets, and reduce 12-HETE in mouse/human beta cells. The compounds can also be used in methods for treating or preventing a 12-lipoxygenase mediated disease or disorder.
C07D 235/30 - Nitrogen atoms not forming part of a nitro radical
C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 277/52 - Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
C07D 211/28 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
C07D 213/76 - Nitrogen atoms to which a second hetero atom is attached
C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.
Board of Governors for Higher Education, State of Rhode Island and Providence Plantations (USA)
Inventor
Doncel, Gustavo F.
Parang, Keykavous
Agarwal, Hitesh Kumar
Abstract
The present invention relates to fatty acid and fatty alcohol substituted nucleoside derivatives and nucleoside and nucleoside derivatives substituted on multivalent scaffolds (e.g., polymers, peptides, polycarboxylic acid substituted compounds, compounds containing polycycloSaligenyl groups) that display potent anti-HIV activity. Furthermore, they show enhanced activity against multi-drug resistant, R5, and cell-associated virus. Some of them also display activity against other sexually transmitted pathogens and sperm. The present invention provides their methods of synthesis, composition of matter, and methods of use. Emphasis is placed on their application as topical microbicides to treat or prevent sexual transmission of disease, especially HIV/AIDS.
C07D 411/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
The present invention provides novel synthetic peptides (including the TZIP peptide) as oncogenic and genetic modulators, including genetics of viruses, as well as methods of making and using the same. These peptides are useful for inhibiting the proliferation of cancer cells characterized as having amplified c-MYC genes. The invention provides methods for the therapeutic uses of the peptides in the treatment of various cancers including small cell lung carcinoma, prostate cancer, lymphoma, brain tumors, colon cancer, bladder cancer, AML, malignant melanoma, mesothelioma, and cancers of head and neck. The peptides are also useful in the treatment of and prevention of transmission of HIV and treatment of expanded nucleotide repeat diseases, including certain currently untreatable and debilitating diseases.
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Methods to preserve and/or protect beta cell function by contacting a population or preparation of pancreatic cells, beta cells and/or islets with an inhibitor of NADPH oxidase-1 (NOX-1). Methods of treating a subject for diabetes by administering a therapeutically effective amount of a NOX-1 inhibitor to the subject.
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07D 279/20 - [b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
30.
4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SANTA CRUZ (USA)
THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THOMAS JEFFERSON UNIVERSITY (USA)
Inventor
Maloney, David, J.
Luci, Diane, K.
Jadhav, Ajit
Holman, Theodore
Nadler, Jerry, L.
Holinstat, Michael
Taylor-Fishwick, David
Simeonov, Anton
Yasgar, Adam
Mckenzie, Steven E.
Abstract
Human lipoxygenases (LOXs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Platelet-type 12-(S)-LOX (12-LOX) is of particular interest because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Disclosed herein is the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3- methoxybenzyl)amino)benzenesulfonamide-based scaffold. The compounds display nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In addition to possessing favorable ADME properties, the compounds also inhibit PAR-4 induced aggregation and calcium mobilization in human platelets, and reduce 12-HETE in mouse/human beta cells. The compounds can also be used in methods for treating or preventing a 12- lipoxygenase mediated disease or disorder.
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
31.
METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1
Methods of preserving and/or protecting pancreatic beta cells by inhibiting NOX-1. In a further aspect, NOX-1 inhibitors are administered to a subject in order to preserve and/or protect beta cells in the prevention or treatment of diabetes. NOX-1 inhibitors are also disclosed; The method can be used to preserve beta cell/ islet survival in vitro, or in vivo in cells exposed to stressful stimuli including but not limited to inflammation, inflammatory cytokines, high glucose, or elevated free fatty acids.
Disclosed are devices for reducing postpartum hemorrhage, including a belt having a fastener for securing the belt around a patient's body, a bladder being inflatable with air and adapted to be placed over the patient's abdomen for applying selective external pressure to the patient's uterus, a manual pump operabiy connected to the bladder to change air pressure of the bladder, and a pressure gauge for indicating the air pressure. Methods for using the devices are also disclosed.
A computer aided system, apparatus and method for addressing routine and emergency situations. In one example, an electronic command device is operable to receive a command, such that the command device provides at least one of a visual and audio representation of at least one instruction for addressing the situation in response to the command. A target electronic device receives an order from the command device and provides at least one of a visual and audio representation of the order. The electronic command device and the target device communicate with each other to monitor the status of carrying out the command.
The present invention provides novel synthetic peptides (including the TZIP peptide) as oncogenic and genetic modulators, including genetics of viruses, as well as methods of making and using the same. These peptides are useful for inhibiting the proliferation of cancer cells characterized as having amplified c-MYC genes. The invention provides methods for the therapeutic uses of the peptides in the treatment of various cancers including small cell lung carcinoma, prostate cancer, lymphoma, brain tumors, colon cancer, bladder cancer, AML, malignant melanoma, mesothelioma, and cancers of head and neck. The peptides are also useful in the treatment of, and prevention of transmission of, HIV and treatment of expanded nucleotide repeat diseases, including certain currently untreatable and debilitating diseases.
The present invention provides biomarkers that are useful in determining whether a subject has cancer, specifically prostate cancer. Specifically, betaine, malate, proline, N-acetylaspartate, uracil, xanthine, cysteine, alanine, and N-acetylglucosamine can be used to diagnose an individual with prostate cancer, one at risk for developing prostate cancer, and/or to determine the prognosis of a subject with prostate cancer. This invention also relates to multiplexed assays for quantitating such biomarkers.
Methods, systems, and non-transitory computer program products are disclosed. Embodiments of the present, invention can include providing a performance model of a procedure, the performance model based at least in part on one or more previous performances of the procedure. Embodiments can further include obtaining performance data while the procedure is performed, the performance data based at least in pari on sensor data received from one or more motion-sensing devices. Embodiments can further include determining a performance metric of the procedure, the performance metric determined by comparing the performance data with the performance model. Embodiments can further include outputting results, the results based on the performance metric.
The present invention provides biomarkers that are useful in determining whether a subject has type 1 diabetes or is at risk for developing type I diabetes. Specifically, syncollin, pancreatic triacylglycerol lipase, as well as fragments and variants of these proteins can be used to diagnose an individual with type I diabetes or one at risk for developing type I diabetes. Additional type I diabetes biomarkers are also provided.
A method of extracting and measuring one or more biochemicals from a biological sample, comprises immersing the biological sample in an organic solvent, whereby one or more biochemicals present in the biological sample are extracted into the organic solvent; separating the biological sample from the free organic solvent; and measuring the level(s) of the one or more biochemicals extracted into the organic solvent, wherein the biological sample remains analyzable by histological analysis.
A device for removing a cerclage suture has a shaft sized and shaped to extend from a proximal end outside a vagina to a distal end near a cervix. The shaft also has a blunt end located at the distal end of the shaft and having a taper for allowing the blunt end to pass between a cerclage suture and cervical mucosa without cutting the mucosa and to move the suture away from the mucosa. The device includes a movable cutter at the distal end of the shaft and being movable between an open non-cutting position and a closed cutting position for cutting the suture. The device also includes an actuator for causing the cutter to be moved from the open position to the closed position to cut the suture.
A61B 17/10 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for applying or removing wound clampsWound clamp magazines
Provided is a diagnostic test for S. haematobium, using a differential filter enrichment method on a urine sample and a colorimetric assay to detect the patient's own anti- schistosome antibodies on the surface of S. haematobium eggs. Also provided is a kit for performing the diagnostic test.
The disclosure provides peptide compounds that regulate the complement system and methods of using these compounds. Specificall the disclosure provides an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The peptide compounds disclosed include peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and/or substitutions, deletions and/or substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The disclosure further provides pharmaceutical compositions comprising therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.
A method of extracting and measuring one or more biochemicals from a biological sample, comprises immersing the biological sample in an organic solvent, whereby one or more biochemicals present in the biological sample are extracted into the organic solvent; separating the biological sample from the free organic solvent; and measuring the level(s) of the one or more biochemicals extracted into the organic solvent, wherein the biological sample remains analyzable by histological analysis.
THE UNITED STATES OF AMERICA, as represented by the secretary, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
EASTERN VIRGINIA MEDICAL SCHOOL (USA)
THOMAS JEFFERSON UNIVERSITY (USA)
Inventor
Maloney, David J.
Holman, Theodore
Jadhav, Ajit
Simeonov, Anton
Bantukallu, Ganesha Rai
Nadler, Jerry L.
Holinstat, Michael
Abstract
Disclosed are inhibitors of human 12-lipoxygenase of Formula (I) or (II), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating or preventing a 12-lipoxygenase mediated disease or disorder, e.g., diabetes. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal.
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
44.
TREATMENT OF DIABETES AND DISORDERS ASSOCIATED WITH VISCERAL OBESITY WITH INHIBITORS OF HUMAN ARACHIDONATE 12 LIPOXYGENASE AND ARACHIDONATE 15-LIPOXYGENASE
A basis for understanding the arachidonate 12-lipoxygenase pathway, as well as and methods and kits for inhibiting the arachidonate 12-lipoxygenase pathway for the treatment, reversal, reduction, modulation or prevention of disease states and conditions related to type 1 or type 2 diabetes, are disclosed. Also disclosed are inflammatory forms of AL0X12 and 15, which are selectively expressed in omental adipose tissue of obese humans. Inhibitors of ALOX 12 and 15 can be used to treat, prevent, modulate or reduce complications associated with increased visceral obesity and inflammation, including type 2 diabetes. Also disclosed are methods for developing selective ALOX inhibitors for treating or reducing complications associated with increased visceral obesity and inflammation.
A device for occluding a cervix has an elongated conduit sized and shaped to extend from a proximal end outside the vagina to a distal end near the cervix. A loop sized to fit around an exocervix is provided at the distal end. The loop is sufficiently flexible to be tightened and loosened around the exocervix. The device can include a rod inside the conduit. The rod has a distal end and a proximal end, and the loop is joined to the distal end of the rod. Moving the rod longitudinally relative to the conduit tightens or loosens the loop. The ends of the loop can also extend out through the proximal end of the conduit. Pulling on the ends through the conduit tightens the loop.
A61F 11/00 - Methods or devices for treatment of the ears or hearing sense Non-electric hearing aidsMethods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing senseProtective devices for the ears, carried on the body or in the hand
A transvaginal ultrasound probe speculum is designed for use with a generally cylindrical elongated ultrasound probe. The speculum has an elongated blade having a proximal end and a distal end, and a connector, such as a collar. The speculum has a lever that cooperates with the collar and the elongated blade for pivoting the blade relative to the ultrasound probe so that the blade and the ultrasound probe serve as the blades of the speculum.
Board of Governors for Higher Education, State of Rhode Island and Providence Plantations (USA)
Inventor
Doncel, Gustavo F.
Parang, Keykavous
Agarwal, Hitesh Kumar
Abstract
The present invention relates to fatty acid and fatty alcohol substituted nucleoside derivatives and nucleoside and nucleoside derivatives substituted on multivalent scaffolds (e.g., polymers, peptides, polycarboxylic acid substituted compounds, compounds containing polycycloSaligenyl groups) that display potent anti-HIV activity. Furthermore, they show enhanced activity against multi-drug resistant, R5, and cell-associated virus. Some of them also display activity against other sexually transmitted pathogens and sperm. The present invention provides their methods of synthesis, composition of matter, and methods of use. Emphasis is placed on their application as topical microbicides to treat or prevent sexual transmission of disease, especially HIV/AIDS.
Methods for forming activated platelet gels using nsPEF's and applying the activated gels to wounds, such as heart tissue after myocardial infarction. The platelets are activated by applying at least one nsPEF with a duration between about 10 picoseconds to 1 microsecond and electrical field strengths between about 10 kV/cm and 350 kV/cm.
The invention provides an apparatus and method for measuring the blood glucose level and physical activity of an individual, and providing an individualized prediction of the blood glucose level of the individual over time based upon the measurements. The individualized prediction is updated in a recursive manner as additional measurements are received. Incentives are determined and provided for maintaining a blood glucose level within a threshold of the individualized predicted blood glucose value and for achieving benchmark levels of physical activity and exertion.
The invention provides biomarkers that can discriminate between prostate cancer and normal tissue as well as identification of associated metastatic disease. One biomarker was identified as a peptide fragment of MEKK2. Methods of diagnosing prostate cancer, including metastatic cancer, by detecting the differential expression of one or more biomarkers are also provided.
The present invention provides a system, method and medium for simulating medical conditions to facilitate medical training, that utilizes a roaming device configured to be mobile; a positioning device configured to determine location information of the roaming device; and a computing device configured to receive the location information, compare the location information with a predetermined set of regions, and transmit information indicative of a medical condition when the location information coincides with the predetermined set of regions.
G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
52.
Systems and methods for monitoring and controlling internal pressure of an eye or body part
Systems and methods for automatically monitoring and controlling pressure in a body part are disclosed. The systems include an implantable tube with one open end of the tube implanted in the body part, an implantable valve coupled with the tube having at least one open state and a closed state, an implantable sensor for measuring pressure, and an implantable control device coupled with the sensor and the valve. The control device switches the valve between the at least one open state and the closed state, based on pressure information received from the sensor. When the valve is in the at least one open state, the tube drains fluids from the body part due to a difference of pressure between the open ends of the tube. Methods for using the systems to administer drugs and monitor and control fluid pressures in various biological systems are also disclosed.
A61M 39/28 - Clamping means for squeezing flexible tubes, e.g. roller clamps
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61B 3/16 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring intraocular pressure, e.g. tonometers
A system and method for performing surgical procedures within a body cavity, e.g. abdomen, uses a magnetized device is utilized to allow a surgeon to control intra-abdominal organs and objects. The system and method allows a surgeon to perform an intra-abdominal procedure without the need to position surgical tools inside of the body cavity. Additional surgical ports are not necessary as the magnetized device allows the surgeon to retract or position various objects within the abdomen.
The present invention relates to fatty acid and fatty alcohol substituted nucleoside derivatives and nucleoside and nucleoside derivatives substituted on multivalent scaffolds (e.g., polymers, peptides, polycarboxylic acid substituted compounds, compounds containing polycycloSaligenyl groups) that display potent anti-HIV activity. Furthermore, they show enhanced activity against multi-drug resistant, R5, and cell-associated virus. Some of them also display activity against other sexually transmitted pathogens and sperm. The present invention provides their methods of synthesis, composition of matter, and methods of use. Emphasis is placed on their application as topical microbicides to treat or prevent sexual transmission of disease, especially HIV/ AIDS.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
55.
METHODS FOR REGULATING COMPLEMENT CASCADE PROTEINS USING ASTROVIRUS COAT PROTEIN AND DERIVATIVES THEREOF
The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement- mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
A01N 63/02 - Substances produced by, or obtained from, microorganisms or animals
A01N 63/04 - Microbial fungi; Substances produced thereby or obtained therefrom
Water- and lipid-soluble cannabinoid compounds that are agonists for CBl and CB2 receptors are provided. The cannabinoid compounds are useful for the treatment of retinal neurodegenerative disorders such as glaucoma, diabetic retinopathy and macular degeneration.
A01N 43/02 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom
A01N 43/00 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
57.
SYSTEMS AND METHODS FOR MONITORING AND CONTROLLING INTERNAL PRESSURE OF AN EYE OR BODY PART
Systems and methods for automatically monitoring and controlling pressure in a body part are disclosed. The systems include an implantable tube with one open end of the tube implanted in the body part, an implantable valve coupled with the tube having at least one open state and a closed state, an implantable sensor for measuring pressure, and an implantable control device coupled with the sensor and the valve. The control device switches the valve between the at least one open state and the closed state, based on pressure information received from the sensor. When the valve is in the at least one open state, the tube drains fluids from the body part due to a difference of pressure between the open ends of the tube. Methods for using the systems to administer drugs and monitor and control fluid pressures in various biological systems are also disclosed.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
B65D 81/00 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
A61D 5/00 - Instruments for treating animals' teeth
58.
NANOSECOND PULSED ELECTRIC FIELDS CAUSE MELANOMAS TO SELF-DESTRUCT
Methods for a new, drug-free therapy for treating solid skin tumors through the application of nanosecond pulsed electric fields ('nsPEFs') are provided. In one embodiment of the invention, the cells are melanoma cells, and the applied nsPEFs penetrate into the interior of tumor cells and cause tumor cell nuclei to rapidly shrink and tumor blood flow to stop. This new technique provides a highly localized targeting of tumor cells with only minor effects on overlying skin.
The present invention is directed generally to protecting cells, tissues and organs against the damaging effects of ionizing or other damaging agents associated with radiation or chemotherapy, or degenerative diseases or processes of various organs that elicit the production of free radicals or oxidants such as peroxides, superoxide anions, hydroxyl radicals or nitric oxides, or heavy metal cations. More particularly, the present invention is concerned with methoxypolyethylene glycol thioester chelate methyl esters that are useful as protectors against tissue damage by penetrating the cell membrane to remove electrons from free radical oxidants and remove heavy metals that may react with peroxides to produce the reactive hydroxyl radical, or remove Ca++ that may be released from organelles. These chelate esters will also have utility in reducing intraocular pressure in glaucoma patients.
The present invention discloses biomarkers and biomarker combinations that have prognostic value as predictors of the developmental potential of individual IVF-derived human embryos. In particular, the biomarkers of this invention are useful to classify an embryo with implantation competence after uterine transfer or implantation incompetence. In addition, the biomarkers can be detected by non-invasive methods that do not harm the developing embryo. Also disclosed are kits for the prediction of developmental potential that detect the biomarkers of the invention, as well as methods using a plurality of classifiers to make a probable diagnosis of developmental potential.
G01N 33/537 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
A system, method and medium for standardizing a manner of acquisition and display of ultrasound images. In one embodiment of the invention, a volumetric image of an organ is acquired in a standardized manner. Relationships such as formulas are utilized to automatically generate anatomical planes of interest within the volume that can be displayed independent of the user.
